The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Proteomic Approaches to Tumor Marker Discovery
Abstract
Context.—Current tumor markers for ovarian cancer still lack adequate sensitivity and specificity to be applicable in large populations. High-throughput proteomic profiling and bioinformatics tools allow for the rapid screening of a large number of potential biomarkers in serum, plasma, or other body fluids. Objective.—To determine whether protein profiles of plasma can be used to identify potential biomarkers that improve the detection of ovarian cancer. Design.—We analyzed plasma samples that had been collected between 1998 and 2001 from patients with sporadic ovarian serous neoplasms before tumor resection at various International Federation of Gynecology and Obstetrics stages (stage I [n = 11], stage II [n = 3], and stage III [n = 29]) and from women without known neoplastic disease (n = 38) using proteomic profiling and bioinformatics. We compared results between the patients with and without cancer and evaluated their discriminatory performance against that of the cancer antigen 125 (CA125) tumor marker. Results.—We selected 7 biomarkers based on their collective contribution to the separation of the 2 patient groups. Among them, we further purified and subsequently identified 3 biomarkers. Individually, the biomarkers did not perform better than CA125. However, a combination of 4 of the biomarkers significantly improved performance (P ≤ .001). The new biomarkers were complementary to CA125. At a fixed specificity of 94%, an index combining 2 of the biomarkers and CA125 achieves a sensitivity of 94% (95% confidence interval, 85%–100.0%) in contrast to a sensitivity of 81% (95% confidence interval, 68%–95%) for CA125 alone. Conclusions.—The combined use of bioinformatics tools and proteomic profiling provides an effective approach to screen for potential tumor markers. Comparison of plasma profiles from patients with and without known ovarian cancer uncovered a panel of potential biomarkers for detection of ovarian cancer with discriminatory power complementary to that of CA125. Additional studies are required to further validate these biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Classification And Regression Trees
Breiman, L., Friedman, J. H., Olshen, R. A., & Stone, C. J. (2017) · doi:10.1201/9781315139470 · Cited by 11,417
Cancer Incidence in Five Continents
(1966) · doi:10.1007/978-3-642-85849-9 · Cited by 5,936
Cited by
Zhang, Z., Bast, R. C., Yu, Y., Li, J., Sokoll, L. J., Rai, A. J., Rosenzweig, J. M., Cameron, B., Wang, Y. Y., Meng, X.-Y., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0746 · Cited by 934
Self-citationRevisiting biomarker discovery by plasma proteomics
Geyer, P. E., Holdt, L. M., Teupser, D., & Mann, M. (2017) · Molecular Systems Biology · doi:10.15252/msb.20156297 · Cited by 917
Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool
Diamandis, E. P. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r400007-mcp200 · Cited by 631
A data review and re-assessment of ovarian cancer serum proteomic profiling
Sorace, J. M., & Zhan, M. (2003) · BMC Bioinformatics · doi:10.1186/1471-2105-4-24 · Cited by 336
Characterization of serum biomarkers for detection of early stage ovarian cancer
Kozak, K. R., Su, F., Whitelegge, J. P., Faull, K., Reddy, S., & Farias‐Eisner, R. (2005) · PROTEOMICS · doi:10.1002/pmic.200500093 · Cited by 311
Metadata
- Authors
- Rai, A. J., Zhang, Z., Rosenzweig, J., Shih, I.-M., Pham, T., Fung, E. T., Sokoll, L. J., & Chan, D. W.
- Venue
- Archives of Pathology & Laboratory Medicine
- Published
- 2002-12-01
- Volume
- 126
- Issue
- 12
- Pages
- 1518-1526
- ISSN
- 0003-9985 (ISSN-L)
- 1543-2165
- OpenAlex
- W1730869288
- Cited by
- 219
- References
- 2
- FWCI
- 21.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proteomic Approaches to Tumor Marker Discovery. https://app.cochat.ai/papers/10.5858/2002-126-1518-pattmd
- The paper
- Rai, A. J., Zhang, Z., Rosenzweig, J., Shih, I.-M., Pham, T., Fung, E. T., Sokoll, L. J., & Chan, D. W. (2002). Proteomic Approaches to Tumor Marker Discovery. Archives of Pathology & Laboratory Medicine. https://doi.org/10.5858/2002-126-1518-pattmd
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.